Milestones in Rheumatoid Arthritis

Following completion of the program, participants should be able to:

Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Temple University School of Medicine designates this educational activity for a maximum of 2 AMA Physician's Recognition Award Category 1 Credit(s)^™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

It is the policy of Temple University School of Medicine, The Albert J. Finestone, MD Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).

The information presented at this CME program represents the views and opinions of the individual presenters and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System, or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including, without limitation, FDA-approved uses and any off-label uses.

Daniel E. Furst, MD, has received grant/research support from Actelion Pharmaceuticals U.S., Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Gilead Sciences, Inc.; National Institutes of Health; Novartis Pharmaceuticals Corporation; Roche Pharmaceuticals; UCB, Inc.; Abbott Laboratories; GlaxoSmithKline; Amgen Inc.; Celgene Corporation; Centocor, Inc.; Wyeth Pharmaceuticals; Xoma (US) LLC; Tap Pharmaceuticals Products Inc.; and Encysive Pharmaceuticals Inc. He is a member of the speakers bureau for Abbott Laboratories; Actelion Pharmaceuticals U.S., Inc.; Bristol-Meyers Squibb Company; Genentech, Inc.; UCB, Inc.; and Encysive Pharmaceuticals Inc.

Philip J. Mease, MD, has received grant/research support from Abbott Laboratories; Bristol-Myers Squibb Company; Biogen Idec Inc.; Centocor, Inc., Genentech, Inc.; and Wyeth Pharmaceuticals. He has been a consultant for Abbott Laboratories; Amgen Inc.; Bristol-Myers Squibb Company; Centocor, Inc.; Genentech, Inc.; Roche Pharmaceuticals; Wyeth Pharmaceuticals; and UCB, Inc. He is a member of the speakers bureau for Abbott Laboratories; Amgen Inc.; Bristol-Myers Squibb Company; Biogen Idec Inc.; Centocor, Inc.; Genentech, Inc.; and Wyeth Pharmaceuticals.

Josef S. Smolen, MD, has been a consultant for Abbott Laboratories; sanofi-aventis U.S. LLC; Bristol-Myers Squibb Company; Centocor, Inc.; Roche Pharmaceuticals; and UCB, Inc. He is on the advisory board for Roche Pharmaceuticals.

Steven Berney, MD, has been a consultant for Genentech, Inc. He is a member of the speakers bureau for Novartis Pharmaceuticals Corporation.

Peter L. Salgo, MD, , has no relationships with commercial entities related to the health care industry to disclose.
All conflicts were resolved.